Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

On Monday, analysts at Morgan Stanley reiterated their Overweight rating on Gilead Sciences, Inc. (NASDAQ:GILD), while ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Analysts raised concerns about potential delays in reimbursement and policy support affecting the Lenacapavir launch. Gilead Sciences is poised for significant growth opportunities with the ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Gilead Sciences recently experienced a significant ... highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial ...

(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in ...